Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. [electronic resource]
Producer: 20110701Description: 347-53 p. digitalISSN:- 1879-355X
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Brain Neoplasms -- drug therapy
- Chemotherapy, Adjuvant -- methods
- Dexamethasone -- administration & dosage
- Diarrhea -- chemically induced
- Disease-Free Survival
- Drug Administration Schedule
- Enzyme Activators -- administration & dosage
- ErbB Receptors -- antagonists & inhibitors
- Female
- Gefitinib
- Gene Amplification -- genetics
- Genes, erbB-1 -- genetics
- Glioblastoma -- drug therapy
- Humans
- In Situ Hybridization, Fluorescence
- Male
- Middle Aged
- Quinazolines -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.